References
  1. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747-752.
  2. Ko LJ, Prives C. p53: Puzzle and Paradigm. Genes Dev. 1996;10(9):1054-1072.
  3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323‐331.
  4. Hwang S-J, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet. 2003;72(4):975-983.
  5. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1233–1238.
  6. Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673-3681.
  7. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat . 2007;28(6):622‐629.
  8. Rieber J, Remke M, Hartmann C, Korshunov A, Burkhardt B, Sturm D, et al. Novel Oncogene Amplifications in Tumors from a Family with Li-Fraumeni Syndrome. Genes, Chromosomes & Cancer. 2009;48(7):558-568.
  9. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol. 2015; 33(20):2279-87.
  10. Living LFS. c2015-2020 [cited 2020 May 31]. Li-Fraumeni Education and Early Detection Program (LEAD). Available from www.livinglfs.org/wp-content/uploads/2016/03/LEAD-Pediatric-screening-program-2016.pdf.
  11. Bojadzjeva J, Behrang A, Day S F, Jackson TL, Thomas PS, Willis BJ, et al. Whole body magnetic imaging ( WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Familial Cancer. 2018; 17(2):287-294.
  12. Mata-Mbemba D, Zapotocky M, Laughlin S, Taylor MD, Ramaswamy V, Raybaud C. MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. Am J Neuroradiol. 2018; 39(5): 945-955.
  13. Koral K, Zhang S, Gargan L, Moore W, Garvey B, Fiesta M, et al. Diffusion MRI Improves the Accuracy of Preoperative Diagnosis of Common Pediatric Cerebellar Tumors among Reviewers with Different Experience Levels. Am J Neuroradiol. 2013; 34(12):2360-2365.
  14. The International Agency for Research on Cancer. WHO Classification of Tumours of the Central Nervous System. Revised 4thed. Lyon: World Health Organization; 2016. p. 190.
  15. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011; 12(6):559-567.
  16. Villani A, Tabori U, Shore A, Wasserman JD, Stephens D, Kim RH, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016; 17(9):1295-1305.
  17. Yeom KW, Mobley BC, Lober RM, Andre JB, Partap S, Vogel H, et al. Distinctive MRI Features of Pediatric Medulloblastoma Subtypes. American Journal of Roentgenol. 2013; 200(4): 895-903.